1656 related articles for article (PubMed ID: 18599183)
21. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
[TBL] [Abstract][Full Text] [Related]
22. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
[TBL] [Abstract][Full Text] [Related]
23. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease.
Yoshida Y; Hirano T; Son G; Iimuro Y; Imado T; Iwasaki T; Fujimoto J
Am J Physiol Gastrointest Liver Physiol; 2007 Dec; 293(6):G1114-23. PubMed ID: 17761834
[TBL] [Abstract][Full Text] [Related]
25. Sirolimus promotes tolerance for donor and recipient antigens after MHC class II disparate bone marrow transplantation in rats.
Jäger MD; Liu JY; Timrott KF; Popp FC; Stoeltzing O; Lang SA; Piso P; Geissler EK; Schlitt HJ; Dahlke MH
Exp Hematol; 2007 Jan; 35(1):164-70. PubMed ID: 17198885
[TBL] [Abstract][Full Text] [Related]
26. Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice.
Perreault C; Allard A; Brochu S; Poupart C; Fontaine P; Bélanger R; Gyger M
Bone Marrow Transplant; 1990 Aug; 6(2):127-35. PubMed ID: 2145050
[TBL] [Abstract][Full Text] [Related]
27. Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT.
Li JM; Giver CR; Waller EK
Exp Hematol; 2006 Jul; 34(7):895-904. PubMed ID: 16797417
[TBL] [Abstract][Full Text] [Related]
28. Effects of T cell depletion in radiation bone marrow chimeras. I. Evidence for a donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD.
Sykes M; Sheard M; Sachs DH
J Immunol; 1988 Oct; 141(7):2282-8. PubMed ID: 3049804
[TBL] [Abstract][Full Text] [Related]
29. Prevention of graft-versus-host disease by intra-bone marrow injection of donor T cells.
Fukui J; Inaba M; Ueda Y; Miyake T; Hosaka N; Kwon AH; Sakaguchi Y; Tsuda M; Omae M; Kamiyama Y; Ikehara S
Stem Cells; 2007 Jun; 25(6):1595-601. PubMed ID: 17446564
[TBL] [Abstract][Full Text] [Related]
30. Complete allogeneic hematopoietic chimerism achieved by in utero hematopoietic cell transplantation and cotransplantation of LLME-treated, MHC-sensitized donor lymphocytes.
Hayashi S; Hsieh M; Peranteau WH; Ashizuka S; Flake AW
Exp Hematol; 2004 Mar; 32(3):290-9. PubMed ID: 15003315
[TBL] [Abstract][Full Text] [Related]
31. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
[TBL] [Abstract][Full Text] [Related]
32. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
33. Intermediate TCR cells can induce graft-versus-host disease after allogeneic bone marrow transplantation.
Weerasinghe A; Kawamura T; Moroda T; Seki S; Watanabe H; Abo T
Cell Immunol; 1998 Apr; 185(1):14-29. PubMed ID: 9636679
[TBL] [Abstract][Full Text] [Related]
34. Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.
Erdmann AA; Jung U; Foley JE; Toda Y; Fowler DH
Biol Blood Marrow Transplant; 2004 Sep; 10(9):604-13. PubMed ID: 15319772
[TBL] [Abstract][Full Text] [Related]
35. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
Du B; Li DP; Xu KL; Pan XY
Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
[TBL] [Abstract][Full Text] [Related]
36. Interferon-gamma-mediated prevention of graft-versus-host disease: development of immune competent and allo-tolerant T cells in chimeric mice.
Brok HP; Vossen JM; Heidt PJ
Bone Marrow Transplant; 1997 Mar; 19(6):601-6. PubMed ID: 9085739
[TBL] [Abstract][Full Text] [Related]
37. The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model.
Fujioka T; Taniguchi Y; Masuda T; Nishida S; Ikegame K; Kawakami M; Tsuboi A; Hosen N; Murakami M; Oji Y; Oka Y; Sugiyama H; Kawase I; Ogawa H
Transpl Immunol; 2003; 11(2):187-95. PubMed ID: 12799203
[TBL] [Abstract][Full Text] [Related]
38. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.
Soderling CC; Song CW; Blazar BR; Vallera DA
J Immunol; 1985 Aug; 135(2):941-6. PubMed ID: 3891856
[TBL] [Abstract][Full Text] [Related]
39. Chimerism and tolerance: from freemartin cattle and neonatal mice to humans.
Jankowski RA; Ildstad ST
Hum Immunol; 1997 Feb; 52(2):155-61. PubMed ID: 9077564
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of transient treatment with FK506 in the early phase on cyclophosphamide-induced bone marrow chimerism and transplant tolerance across MHC barriers.
Okayama J; Ko S; Kanehiro H; Kanokogi H; Nakajima Y
J Surg Res; 2006 Jun; 133(2):61-8. PubMed ID: 16376943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]